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Summary
QUESTIONS UNDER STUDY: Lung cancer belongs to
the most common cancers in Switzerland. We examined
trends in lung cancer incidence, with focus on sex, histo-
logy and laterality, in the Canton of Zurich since 1980.
MATERIAL AND METHODS: Registry data consisting of
16 798 lung cancer cases from 1980 to 2010 were analysed.
Cases were classified into adenocarcinoma (ADC), squam-
ous cell carcinoma (SCC), small-cell carcinoma (SCLC),
large cell tumour and carcinoid tumour. Age-standardised
(European standard) incidence rates (IR) per 100 000
person-years, male-to-female incidence-rate ratio (M/F-
IRR), and left-to-right lung incidence-rate ratio (L/R-IRR)
were calculated.
RESULTS: Over the study period, ADC occurred most
frequently (31.9%), followed by SCC (29.1%), SCLC
(15.4%), large cell carcinoma (6.3%), and carcinoid tu-
mour (1.5%). Other/unspecified subtypes accounted for
15.7%. In men, the IR of SCC decreased from 34.2/100 000
(95% confidence interval [CI] 32.5–35.9) in 1980 to 12.8/
100 000 (12.0–13.6) in 2010, but increased in women from
3.4/100 000 (2.7–4.0) to 4.0/100 000 (3.4–4.5). The IR of
ADC increased in women from 5.1/100 000 (4.1–5.8) to
12.6/100 000 (11.8–13.4) and in men from 15.1/100 000
(14.0–16.3) to 19.4/100 000 (18.4–20.4). Overall M/F-IRR
was 2.61; the highest ratio (5.8) was seen for SCC and the
lowest (0.77) for carcinoid tumour. All histological sub-
types showed a higher susceptibility of the right lung.
CONCLUSION: Our data reflect the global increase of
lung cancer in women. ADC increased over time in women
and men, whereas SCC decreased markedly among men.
These trends may have occurred owing to changes in
smoking behaviour and cigarette composition.
Key words: lung cancer; histology; incidence; time
trends; laterality; Switzerland
Introduction
Lung cancer still causes the largest proportion of cancer
deaths in many countries worldwide [1, 2]. In Switzerland,
lung cancer is the leading cause of cancer death in men
and the second most common cause of cancer death in wo-
men, accounting for 40.3/100 000 deaths in men and 18.7/
100 000 deaths in women (mean mortality rate 2008–2012,
age-standardised, European standard) [3]. Changes in his-
tological subtypes of lung carcinoma and concurrent sex-
specific shifts within the last decades have been reported
globally [4]. Of the five main histomorphological lung car-
cinoma subtypes, adenocarcinoma (ADC) and squamous
cell carcinoma (SCC) are proportionately the most import-
ant [5]. A shift from SCC to ADC has been observed in
men with a coincident increase of SCC and ADC in wo-
men [5]. Less studied is the phenomenon of quantitative
susceptibility of one side of the lung. As the right and left
lung are different in volume, it has been hypothesised that
lung cancer incidence coincides with this asymmetry [6].
Although there are several risk factors for lung carcinoma,
such as environmental and occupational causes, genetic
and sex-specific factors, nutrition, overweight, and maybe
even human papilloma virus infection, tobacco smoking is
considered the main risk factor [7–9]. Smoking accounts
for up to 90% of lung carcinoma, with a delay of occur-
rence of around 20–30 years [10, 11]. Therefore, lung can-
cer incidence reflects the smoking behaviour of a popula-
tion [12], while international lung cancer incidence reflects
the stage of the tobacco epidemic [13]. Figure 1 depicts the
tobacco epidemic in Switzerland [14–16], where smoking
prevalence in women was 24.1% in 1992 and 25.5% in
2002, and in men was 36.5% in 1992 and 36% in 2002
[16]. In the USA, smoking prevalence reached high levels
in the 1950s in men (about 55%) and in the 1960s in wo-
men (about 35%) [17–19], whereas in Switzerland smoking
prevalence peaked in the 1950s in men (about 61%) and in
the 1970s in women (about 29%) [14–16]. A coincident in-
crease of lung cancer incidence was observed in the 1970s
in Europe [13] and in the USA [12]. Lung cancer incid-
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ence in the USA has decreased in men since the 1980s and
in women after 2000, reflecting changes in the smoking
epidemic [20, 21]. Because of different smoking behaviour
among women compared with men, i.e. lower smoking pre-
valence and lower numbers of cigarettes smoked per day,
lung cancer in women occurred later and will likely not
reach as high levels as the epidemic did among men [11].
To provide information about changes in trends over the
last three decades, data of the population-based Cancer Re-
gistry of the Canton of Zurich were analysed with a focus
on sex-specific changes as well as histomorphological and
topographic characteristics.
Material and methods
Data source
The canton of Zurich is, with respect to population, the
largest Swiss canton with 1 359 712 inhabitants in 2010.
Anonymised data of the Cancer Registry of the Canton of
Zurich were analysed for changes in trends in lung cancer
incidence by histological subtype, age, sex and laterality.
Epidemiological data are available since 1980. The Cancer
Registry provides general demographic data about the pa-
tient, data about the histological type, date and type of dia-
gnosis, the site of the tumour, and data about treatment and
survival status.
The analytical cohort consisted of 16 985 primary incident
cases of lung cancer in the Canton of Zurich from 1980 to
2010. One hundred eighty-seven of the 16 985 cases were
excluded from the study because of missing age informa-
tion.
Statistical analysis
Cancer data of the Swiss Canton of Zurich were filtered
using International Classification of Diseases (ICD) codes
(C33 and C34, 7 cases C809 with cytological or histolo-
gical confirmation). Lung cancer was grouped using the
ICD for Oncology (ICD-O-3) [22] – five histologic sub-
types and one group with others and not otherwise speci-
fied types (see appendix). Of all cases, 74.5% were histolo-
gically confirmed, and 18% were cytologically confirmed.
In 2% of the cases, the only information in the registry was
from a death certificate.
Incidence rates (IRs, cases per 100 000 person-years) were
calculated using a weighted average of rates in 5-year age
Figure 1
Smoking prevalence in Switzerland, 1955–2012. Source: 1955 [14],
1975–1981 [15], 1992–2012 [16].
groups according to the European standard [23]. IRs for
ten-year age cohorts (40–49, 50–59, 60–69, 70–79 and ≥80
years) were calculated for the major histological subtypes
ADC, SCC and small cell carcinoma (SCLC). Confidence
intervals were calculated for all IRs using the delta method
(confidence intervals of the log rates and back transforma-
tion to rates).
Male-to-female incidence-rate ratio (M/F-IRR) and left-to-
right lung incidence-rate ratio (L/R-IRR) were calculated
to compare sex- or site-specific susceptibility. To compare
the histological types shown in table 1, the following tests
were used: analysis of variance for continuous data, chi-
square for categorical data, and Poisson regression for IR
and L/R-IRR. To study the effect of sex, incidence year,
and age for each major histological subtype we performed
a multivariable Poisson regression. Poisson regression was
only applied for the three major histological types owing to
larger sample size and clinical relevance.
Results
Of all cases, 72.3% were male and 27.7% were female,
with a mean age of 67.5 (SD ± 11.2; table 1). The absolute
number of lung cancer cases in the Canton of Zurich in-
creased from 1980 to 2010. In the decade 1980–1989, 4796
cases were reported, 5342 cases in 1990–1999 (+11.4%)
and 6660 cases in 2000–2010 (+24.7%). Over the whole
period, ADC was most common (31.9%), followed by SCC
Figure 2
Trends in lung cancer incidence in men by histological type in the
Canton of Zurich, Switzerland, 1980–2010. Rates are age adjusted
to the standard European population.
Figure 3
Trends in lung cancer incidence in women by histological type in
the Canton of Zurich, Switzerland, 1980–2010. Rates are age
adjusted to the standard European population. NOS = not
otherwise specified.
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(29.1%), others and not otherwise specified (15.7%),
SCLC (15.4%), large cell carcinoma (6.3%), and carcinoid
tumour (1.5%).
The mean age-standardised IR in men decreased from 80.0
(1980–1989) to 56.3 (2000–2010), while there was an in-
crease in IR per decade from 18.5 (1980–1989) to 29.5
(2000–2010) in women. The M/F-IRR was 2.6 for all lung
cancer sites, with the highest ratio for SCC (5.8) and the
lowest for carcinoid tumour (0.77).
From 1980 to 1989, SCC was the predominant histological
subtype in men. From 1998 to 2010, ADC became the ma-
jor subtype (fig. 2). In women, ADC was the predominant
histological subtype from 1980 onward (fig. 3). For ADC,
there was an increase of IR in women (5.1 to 12.6) and in
men (15.1 to 19.4). A decrease in IR of SCC in men (34.2
to 12.8) occurred over the study period, whereas IR slightly
increased in women (3.4 to 4.0). SCC IR in men peaked in
1989, but the IR in women showed constant levels with a
discrete peak in 2006.
In women, IR of all histological subtypes increased, but in
men an increase occurred only in ADC. ADC accounted for
a larger proportion of lung carcinomas in women (43.7%)
than in men (27.4%). However, IR for every histological
subtype was significantly lower for women than for men.
Sex differences in IR were most evident in SCC and least
in carcinoid tumour.
IR of ADC for age cohorts of over 50-year-old women and
men increased from 1980 until 2010 (fig. 4). The highest
IR in the last decade was observed in men aged 70–79 and
≥80, but a decade earlier in women. IR of SCC showed a
decrease over the years, especially in men aged 70–79 and
≥80 years. The only increase was seen in the women’s age
cohorts of 60–69 and 70–79. IR of SCLC for women was
constant apart from a slight increase in age cohorts 60–69
and 70–79. IR of SCLC of men decreased except for men
≥80 years old.
Results of the Poisson regression confirmed the observa-
tion that the incidence of all three major histological types
was higher among men than women (table 2), and that the
incidence of ADC increased over the observation period,
while the incidence of SCC and SCLC decreased. The in-
cidence of ADC increased with age, whereas the IRRs for
SCC decreased with age; the IRRs for SCLC did not differ
statistically significantly between the age groups. We also
applied a Poisson regression model with interaction terms
between sex and incidence year, as well as sex and age.
Table 1: Characteristics of primary incident lung cancer cases diagnosed in the Canton of Zurich 1980–2010.
All cases Adenocarcinoma Squamous
cell
carcinoma
Small cell
carcinoma
Carcinoid
tumour
Large cell
carcinoma
Others and
NOS
p-value
Variable n = 16 798
(100%)
n = 5357 (31.9%) n = 4895
(29.1%)
n = 2592
(15.4%)
n = 250 (1.5%) n = 1065
(6.3%)
n = 2639
(15.7%)
Age (years) <0.001
Mean ± SD 67.5 ± 11.2 66.2 ± 11.3 68.1 ± 9.9 66.0 ± 10.6 62.1 ± 16.4 65.2 ± 11.4 71.9 ± 11.5
Median 68.2 66.5 68.8 66.5 65.7 65.4 72.9
Quartile 25%; 75% 60.0; 75.8 58.3; 74.7 61.4; 75.5 58.8; 73.9 51.3; 74.6 57.6; 73.5 64.5; 80.7
Sex, n (%) <0.001
Women 4652 (100%) 2034 (43.7%) 720 (15.5%) 701 (15.1%) 141 (3.0%) 305 (6.6%) 751 (16.1%)
Men 12 146 (100%) 3323 (27.4%) 4175 (34.4%) 1891 (15.6%) 109 (0.9%) 760 (6.3%) 1888 (15.6%)
Men/women ratio 2.61 1.63 5.80 2.70 0.77 2.49 2.51
Period of diagnosis, n (%) <0.001
1980–1989 4796 (100%) 1088 (22.7%) 1962 (40.9%) 889 (18.5%) 49 (1.0%) 228 (4.8%) 580 (12.1%)
1990–1999 5342 (100%) 1623 (30.4%) 1594 (29.8%) 829 (15.5%) 93 (1.7%) 386 (7.2%) 817 (15.3%)
2000–2010 6660 (100%) 2646 (39.7%) 1339 (20.1%) 874 (13.1%) 108 (1.6%) 451 (6.8%) 1242 (18.6%)
Laterality unknown, n (%)
Women 584 (12.6%) 185 (9.1%) 40 (5.6%) 97 13.8%) 17 (12.1%) 42 (13.8%) 203 (27.0%) <0.001
Men 1284 (10.6%) 301 (9.1%) 178 (4.3%) 197 (10.4%) 6 (5.5%) 75 (9.9%) 527 (27.9%) <0.001
IR women <0.001
1980–1989, mean IR (95% CI) 18.5
(16.7–20.2)
5.1 (4.5–5.8) 3.4 (2.7–4.0) 3.3 (2.7–4.0) 2.0 (1.0–3.0) 1.7 (1.1–2.2) 2.9 (2.2–3.7)
1990–1999, mean IR (95% CI) 23.5
(21.9–25.0)
8.3 (7.5–9.1) 3.6 (3.1–4.1) 3.9 (3.3–4.5) 1.9 (1.2–2.5) 2.6 (2.1–3.2) 3.2 (2.7–3.7)
2000–2010 mean IR (95% CI) 29.5
(27.9–31.0)
12.6 (11.8–13.4) 4.0 (3.4–4.5) 3.8 (3.3–4.3) 2.2 (1.4–3.0) 2.4 (1.9–2.8) 4.5 (3.9–5.2)
IR men <0.001
1980–1989 mean, IR (95% CI) 80.0
(77.1–82.8)
15.1 (14.0–16.3) 34.2
(32.5–35.9)
14.1
(13.0–15.2)
2.3 (1.3–3.3) 4.7 (3.8–5.5) 9.5 (8.5–10.5)
1990–1999 mean, IR (95% CI) 69.0
(66.6–71.3)
17.8 (16.7–19.0) 22.9
(21.7–24.2)
10.4 (9.5–11.2) 2.2 (1.5–3.0) 5.4 (4.7–6.0) 10.2 (9.3–11.1)
2000–2010 mean, IR (95% CI) 56.3
(54.5–58.2)
19.4 (18.4–20.4) 12.8
(12.0–13.6)
7.4 (6.8–8.0) 2.1 (1.3–2.8) 4.6 (4.0–5.1) 10.2 (9.4–10.9)
L/R-IRR (IR left / IR right) <0.001
Women 0.72 0.65 0.81 0.81 0.78 0.79 0.72
Men 0.83 0.79 0.86 0.82 1.00 0.76 0.86
IR = incidence rate, standardised (European standard); L/R-IRR = left-to-right lung incidence-rate ratio; NOS = not otherwise specified (n = 1983) including non-small cell
carcinoma (n = 455)
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Statistically significant interactions between sex and incid-
ence year and between sex and age were observed for all
histological types combined and partly also for histologic-
al subtypes, such that changes in IR over time depended
on both sex and age group (figs 2–4). For example, the in-
crease in ADC incidence over time was stronger in men
than in women and particularly in men of the two upper age
categories (fig. 4).
For all histological subtypes, there was a higher susceptib-
ility of the right lung, which was more distinct in women
than in men (table 1). In 11.1% of the cases, information
about laterality was not available. L/R-IRR showed statist-
ically significant variations according to histological sub-
type, with the lowest L/R-IRR seen for ADC.
Discussion
From our analysis three major findings have emerged.
First, this study reports an increase of ADC incidence in
the Canton of Zurich in men and women. Second, IR of
SCC decreased in men but not in women. Third, there were
changes in M/F-IRR and L/R-IRR depending on the histo-
logical subtype and the time period.
Figure 4
Trends in lung cancer incidence by sex, major histological type and
age categories in the Canton of Zurich, Switzerland, 1980–2010.
NOS = not otherwise specified.
IR of lung cancer in the Canton of Zurich was much lower
than in the USA over the whole observed period, and will
probably never reach such high levels (peak IR in men:
USA 102.1/100,000 (1984), Canton of Zurich 80.1/
100,000 (1985); in women: USA 53.6/100,000 (2007),
Canton of Zurich 29.4/100,000 (2009)) [12, 21, 24]. There
are few studies of lung cancer incidence in Switzerland, but
more on lung cancer mortality. However, lung cancer mor-
tality rates closely follow IR owing to the high fatality rate
of lung cancer (lung cancer 5-year survival <20% [25]).
Rising lung cancer mortality in Switzerland was observed
from 1950 to the early 1970s among men [26] and an ongo-
ing increase in women [13, 27], although still lower than in
the USA and in many European countries. The lung cancer
mortality rate in Switzerland is one of the lowest in Europe,
especially among men [13, 28]. In Switzerland and many
European countries lung cancer mortality rate among wo-
men increased over the last decade [13, 27]. We observe the
same trend in the Canton of Zurich: IR in women increased
over the observation period.
As in other European countries [4], ADC is the predom-
inant histological subtype in the Canton of Zurich, with a
rising ADC incidence. Our data show an ongoing increase
of ADC incidence and an increase of ADC among men and
women projecting the future mortality burden in the Can-
ton of Zurich. In the USA an increase of ADC incidence
has been observed since 1980 [8, 29–31] with a tempor-
ary decrease of ADC in men up to 2005 [31]. An earlier
study in the Swiss Cantons of Vaud and Neuchâtel from
1974 to 1994 also reported an increase of ADC inciden-
ce among men and women [5]. Even though some studies
showed a higher rate of ADC IR in women than in men
[29, 31, 32], our data show similar results as other studies,
with significantly higher IR of ADC in men than in wo-
men [8, 33, 34]. As for SCC IR, we observed declines dur-
ing 1989 to 2010 in men and a slight increase from 1980 to
2010 in women. The same trends were visible in the Can-
tons of Vaud and Neuchâtel from 1974 to 1994 [5]. SCC IR
in the Canton of Zurich in men reached a peak in 1989, but
there no peak in SCC IR in women was visible. Similarly,
a peak in the mid-1980s and a decrease of SCC IR have
been reported in the USA [31].There is an association with
smoking for all histological subtypes, but for SCLS and
SCC this association is much stronger than it is for ADC
Table 2: Associations of sex, incidence year and age with lung cancer subtypes in the Canton of Zurich, 1980–2010.
Adenocarcinoma Squamous cell carcinoma Small cell carcinoma
IRR* CI IRR* CI IRR* CI
Female 1.00 (reference) 1.00 (reference) 1.00 (reference)Sex
Male 1.94 (1.83–2.06) 7.42 (6.80–8.09) 2.96 (3.39–4.16)
1980 1.00 (reference) 1.00 (reference) 1.00 (reference)
1990 1.29 (1.19–1.39) 0.73 (0.68–0.78) 0.90 (0.77–0.94)
2000 1.65 (1.53–1.77) 0.50 (0.46–0.54) 0.84 (0.60–0.73)
Incidence year
2010 1.91 (1.66–2.20) 0.30 (0.24–0.36) 0.64 (0.30–0.51)
30–39 0.50 (0.42–0.60) 0.46 (0.40–0.54) 0.00 –
40–49 0.62 (0.57–0.68) 0.70 (0.56–0.86) 0.95 (0.50–0.79)
50–59 0.70 (0.65–0.77) 0.61 (0.56–0.66) 1.13 (0.87–1.19)
60–69 1.00 (reference) 1.00 (reference) 1.00 (reference)
70–79 1.32 (1.22–1.43) 1.29 (1.19–1.39) 1.06 (1.37–1.65)
Age (years)
≥80 2.99 (2.72–3.28) 2.53 (2.22–2.87) 1.30 (2.74–3.76)
* Incidence-rate ratios (IRR) are mutually adjusted for sex, incidence year, and age
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[31, 35, 36]. Deeper inhalation of cigarette smoke, changes
in the composition of cigarettes, and the fact that lung can-
cer risk after smoking cessation decreases faster for SCC
and SCLC might have led to the shift towards ADC [12, 18,
36–39]. The fastest decrease of risk after smoking cessation
is seen in SCC [38]. Environmental or dietary factors prob-
ably have minor effects on changes of histological subtypes
in countries with high smoking prevalence rates. Air pollu-
tion in the USA had little impact on the increase of ADC,
as in the USA only 3% of cases are environmentally caused
[37, 40].
The composition of cigarettes has changed remarkably
over time. Therefore, the epidemic data are strongly influ-
enced by different cigarette types [11]. At first, cigarettes
were unfiltered; however, starting in 1950 the proportion
of filtered cigarettes increased in the USA reaching 97.5%
in 1992. In Switzerland, this process advanced even quick-
er [18]. A reduction of SCC but not of ADC risk for life-
time filtered cigarette smoking compared with unfiltered
cigarettes was observed [39]. Tobacco types have different
characteristics. In Switzerland, the predominant type is air-
cured Maryland, a non-blended tobacco [18]. Smoking be-
haviour changed owing to the introduction of low-yield ci-
garettes and the increase of nitrosamines, which are found
in blended cigarettes in high doses and mainly cause ADC
[31, 37, 39]. The lower nicotine content of low-yield cigar-
ettes increases the puff volume and therefore the tar, nicot-
ine and nitrosamine levels in the lung [18, 36, 39]. The in-
vention of filtered cigarettes encouraged deep inhalation,
supporting a shift from tracheal and bronchial exposure to
a more peripheral smoke exposure in the lung [36], which
might have led to an increase in peripheral ADC [41, 42].
In general, there was a decrease in the smoking prevalen-
ce in Switzerland in men from 61% in 1955 to 32.4% in
2012 (fig. 1), and a mainly constant smoking prevalence
in women from 23% in 1955 to 24.2% in 2012 [14–16].
Nevertheless, an increase of smoking prevalence among
men and women was reported in 1997 (fig. 1). Therefore,
antismoking campaigns increased in Switzerland between
1997 and 2007, which generated a reduction of smoking
prevalence from 33% to 28% [16, 43]. Since 2006, res-
taurants in Switzerland have gradually become smoke-free
zones [44]. To improve the future and combat the increas-
ing trends in ADC IR, further campaigns and restrictions
are needed.
Several [45–50], but not all [29, 41, 51–55] studies repor-
ted a higher susceptibility of women than men to develop
lung cancer. However, a recent meta-analysis indicates a
higher risk of diagnosis attributable to cigarette smoking in
men [56]. As in the USA [31], our study shows the highest
rates in M/F-IRR in SCC, intermediate rates in SCC, and
lower rates in ADC. This might be explained by the higher
incidence of ADC in nonsmoking women globally [12,
29, 37] and different smoking behaviour. Women started
smoking later and generally consume lower-tar products
[57]; men tend to smoke more cigarettes per day and inhale
more deeply [48, 58]. Other explanations might include
sex-related differences in nicotine metabolism or interac-
tions of smoking with hormone use in women [12], but fur-
ther research is clearly needed to address these issues.
Our data showed a significantly lower L/R-IRR in ADC
than in SCLC or SCC. One study also reports a higher sus-
ceptibility of the right lung in women and men (L/R-IRR
for women 0.88, L/R-IRR for men 0.86) [6]. Possible ex-
planations include different volumes of the right and left
lung, and unequal smoke exposure according to different
tidal volumes [6] resulting from anatomical characteristics.
The right lung represents 55% of the volume and the left
lung 45%. Furthermore, the right bronchus is shorter and
the branching angle between the trachea and the bronchus
is less than it is on the left side [59].
The advantages of this study are the large sample size and
the continuous data that document changes over three dec-
ades. Our data reflect global and European changes, and
there is great importance in analysing histological sub-
types, since aetiology, identification, diagnosis and thera-
peutic approaches change over the years. However, there
are several limitations of this study. Shifts in diagnostic
procedures and changes in classification may lead to a dia-
gnostic artefact. With the introduction of ICD-O-3 the code
non-small cell carcinoma was added in 2001 and used by
the Cancer Registry of Zurich since 2003. After 2003 the
IR of not otherwise specified large cell carcinoma in the
Canton of Zurich decreased drastically. Non-small cell car-
cinoma and not otherwise specified carcinoma were not
differentiated in our study (further information in the Meth-
ods section). With the invention of new diagnostic meth-
ods, such as immunostaining for FTT-1, a marker for ADC,
a decrease of unspecified carcinoma occurred with a coin-
cident increase of ADC [34]. Additionally, complete indi-
vidual data about smoking behaviour and other risk factors
of lung carcinoma for analysis are missing.
In conclusion, there is an ongoing increase of ADC incid-
ence in the Canton of Zurich, despite a declining trend in
SCC and general lung cancer incidence. In all histologic-
al types, there is a significantly higher susceptibility of the
right lung. Despite a distinct decrease of lung cancer in-
cidence in men (apart from ADC), we do see a continuing
increase of lung cancer incidence in women in the Canton
of Zurich. A critical point to further decrease prevalence
rates of smoking, and thus decrease the burden of lung can-
cer, is to prevent uptake of smoking among adolescents and
young adults, but also efforts to increase smoking cessa-
tion rates among current smokers. However, further efforts
are needed to improve survival of lung cancer patients. Im-
provement in early detection in particular among high-risk
individuals and accuracy of discrimination of histological
types and specific therapy will hopefully increase lung can-
cer survival.
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Appendix: International Classification of Diseases (ICD) codes for group classification
Adenocarcinoma (M: 8015, 8050, 8140, 8141, 8190, 8200, 8211, 8230, 8250-8255, 8260, 8290, 8310, 8430, 8480, 8481, 8490, 8550, 8560),
SCC (M : 8051-8053, 8060, 8070, 8071-8078, 8080-8084)
Small cell carcinoma (M : 8041-8045, 8002)
Large cell carcinoma (M : 8012-8014)
Carcinoid tumor (M : 8240, 8244, 8246, 8249)
Other carcinomas and not otherwise specified types (M : 8000, 8001, 8003-8005, 8010, 8011, 8015, 8020-8022, 8030-8035, 8040, 8046, 8570,
8572, 8573, 8720, 8800, 8801, 8804, 8810, 8815, 8830, 8840, 8852, 8890, 8940, 8972, 8980, 9040, 9041, 9120, 9130, 9240, 9540, 8033)
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Figures (large format)
FUS
Figure 1
Smoking prevalence in Switzerland, 1955–2012. Source: 1955 [14], 1975–1981 [15], 1992–2012 [16].
Figure 2
Trends in lung cancer incidence in men by histological type in the Canton of Zurich, Switzerland, 1980–2010. Rates are age adjusted to the
standard European population.
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Figure 3
Trends in lung cancer incidence in women by histological type in the Canton of Zurich, Switzerland, 1980–2010. Rates are age adjusted to the
standard European population. NOS = not otherwise specified.
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Figure 4
Trends in lung cancer incidence by sex, major histological type and age categories in the Canton of Zurich, Switzerland, 1980–2010. NOS = not
otherwise specified.
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